Delving into the Latest Updates on Bradmer Pharmaceuticals, Inc. with Synapse

Overview

Bradmer Pharmaceuticals, Inc. (Bradmer) is requesting approval to study the safety of Neuradiab® when combined with Bevacizumab (Avastin) therapy given at a minimum of 30 days after Neuradiab administration in patients with a first or second recurrence of glioblastoma multiforme (GBM), in an attempt to manage life threatening recurrence of Grade IV malignant glioma.

Start Date01 May 2009

Sponsor / Collaborator

Bradmer Pharmaceuticals, Inc.

NCT00615186

/ TerminatedPhase 3

A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

The current study will investigate whether the addition of Neuradiab to surgery, radiation and adjuvant chemotherapy (temozolomide) will improve the survival of patients with glioblastoma and whether the drug regimen is safe.

Start Date01 Jun 2008

Sponsor / Collaborator

Bradmer Pharmaceuticals, Inc.

100 Clinical Results associated with Bradmer Pharmaceuticals, Inc.

Login to view more data

0 Patents (Medical) associated with Bradmer Pharmaceuticals, Inc.

Login to view more data

100 Deals associated with Bradmer Pharmaceuticals, Inc.

Login to view more data

100 Translational Medicine associated with Bradmer Pharmaceuticals, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data